Drugs / Umifenovir
Umifenovir
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05184127 | Apr → Sep 2021 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT03787459 | Jan 2019 → Apr 2023 | influenza | Capital Medical University | Completed | No outcome recorded |
| Phase 44 trials · 1 met primary | ||||||
| Phase 4 | NCT04350684 | Apr 2020 | COVID-19 | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT04260594 | Feb → Mar 2020 | COVID-19 | Jieming QU | Completed | Met primary |
| Phase 4 | NCT04255017 | Feb → Jun 2020 | COVID-19 | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01651663 | Sep 2011 → Jun 2015 | influenza | Pharmstandard | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06462417 | Jul 2024 → Jun 2025 overdue | allergic rhinitis | Zheng Liu | Recruiting | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 2/3 | NCT05783206 Background | Feb 2022 → Jul 2023 | COVID-19 | National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia | Completed | No outcome recorded |
| Phase 3 | NCT04501783 Comparator | May → Jul 2020 | COVID-19 | R-Pharm | Completed | No outcome recorded |
| Phase 4 | NCT04286503 Comparator | Feb 2020 → Feb 2021 | COVID-19 | Beijing YouAn Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04254874 Background | Feb → Jun 2020 | COVID-19 | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04252885 Comparator | Jan → Apr 2020 | Coronaviridae infectious disease | Guangzhou 8th People's Hospital | Completed | Missed primary |
| Phase 4 | NCT03851991 Comparator | Aug 2019 → Oct 2023 | chronic obstructive pulmonary disease | Shengjing Hospital | Completed | No outcome recorded |
| — | NCT04273763 Background | Feb → May 2020 | COVID-19 | Second Affiliated Hospital of Wenzhou Medical University | Unknown | No outcome recorded |
| — | NCT04664010 Background | Feb 2020 → Sep 2022 | COVID-19 | Xi'an International Medical Center Hospital | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-05-26 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India glenmarkpharma.com ↗
Glenmark received approval from the Indian regulator to initiate the study |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-05-26 | Glenmark Pharmaceuticals Ltd. India | Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India glenmarkpharma.com ↗ |
| 2009-04-29 | Pharmstandard | ARBIDOL IS EFFECTIVE FOR PREVENTION “SWINE INFLUENZA” pharmstd.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Umifenovir | “standard therapy which included symptomatic treatment as well as etiotropic drugs such as Favipiravir, Umifenovir, Remdesivir, convalescent plasma and interferon α-2b.” NCT05184127 ↗4“Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.” NCT01651663 ↗ “umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine” NCT04501783 ↗ “umifenovir (Arbidol®) - 200 mg 4 times per day for 7 days” NCT05783206 ↗ |
| Known as | Abidol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04254874 ↗ |
| Known as | Arbidol | “umifenovir (Arbidol®) - 200 mg 4 times per day for 7 days” NCT05783206 ↗ |
| Action | Inhibit | “prevents fusion of the viral envelope with cell membranes.” NCT01651663 ↗ |
| Modality | Small molecule | “Arbidol is a non-nucleoside antiviral drug.” NCT03851991 ↗ |
| Route | Oral | “In group B, 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days).” NCT04252885 ↗ |